AKT1 and cancer: A small-molecule Comp34 preferentially targeted TNBC and cancer stem cells and inhibited AKT1/mTOR expression by inhibition of lncRNA NUDT3-AS4, which sponged miR-99s to release the mRNA of AKT1/mTOR from miRNA-dependent decay [45].